Limits...
Evolving treatment approaches for the management of metastatic castration-resistant prostate cancer - role of radium-223.

Mukherji D, El Dika I, Temraz S, Haidar M, Shamseddine A - Ther Clin Risk Manag (2014)

Bottom Line: Radium-223 is a first-in-class alpha particle-emitting radiopharmaceutical approved for the treatment of bone metastatic castration-resistant prostate cancer.Radium-223 is administered intravenously with no requirement for complex shielding and specifically targets areas of bone metastasis.In a randomized placebo-controlled Phase III study, treatment with radium-223 was shown to improve overall survival, time to skeletal-related events, and health-related quality of life.

View Article: PubMed Central - PubMed

Affiliation: Department of Hematology/Oncology, American University of Beirut Medical Center, Beirut, Lebanon.

ABSTRACT
Radium-223 is a first-in-class alpha particle-emitting radiopharmaceutical approved for the treatment of bone metastatic castration-resistant prostate cancer. Radium-223 is administered intravenously with no requirement for complex shielding and specifically targets areas of bone metastasis. In a randomized placebo-controlled Phase III study, treatment with radium-223 was shown to improve overall survival, time to skeletal-related events, and health-related quality of life. Apart from radium-223, the cytotoxic chemotherapy agents docetaxel and cabazitaxel, androgen biosynthesis inhibitor abiraterone acetate, novel anti-androgen enzalutamide, and immunotherapy sipuleucel-T have also been shown to improve survival of men with advanced prostate cancer in Phase III trials. This review will outline current treatment approaches for advanced prostate cancer with a focus on the role of radium-223 in changing treatment paradigms.

No MeSH data available.


Related in: MedlinePlus

Mechanism of action of radium-223.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4043797&req=5

f1-tcrm-10-373: Mechanism of action of radium-223.

Mentions: Alpha particles (composed of two protons and two neutrons) have more than 7,000 times the mass of beta particles, resulting in high linear energy transfer and significantly more biological damage over a very short range (Figure 1). The relatively long range of beta-emitting radiopharmaceuticals may cause significant bone marrow suppression and limit repeated administration.33 The track length of the alpha particle is 0.10 mm (five to ten cell diameters) compared with 0.6 mm for samarium-153 and 2.4 mm for strontium-89, limiting damage to normal tissues.1 Preclinical studies performed in rats demonstrated a significant bone marrow-sparing advantage with radium-223 compared with strontium-89.34 In an experimental bone metastasis model in nude rats, radium-223 was found to be selectively concentrated in bone compared with soft tissues with a dose-dependent increase in symptom-free survival observed.35


Evolving treatment approaches for the management of metastatic castration-resistant prostate cancer - role of radium-223.

Mukherji D, El Dika I, Temraz S, Haidar M, Shamseddine A - Ther Clin Risk Manag (2014)

Mechanism of action of radium-223.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4043797&req=5

f1-tcrm-10-373: Mechanism of action of radium-223.
Mentions: Alpha particles (composed of two protons and two neutrons) have more than 7,000 times the mass of beta particles, resulting in high linear energy transfer and significantly more biological damage over a very short range (Figure 1). The relatively long range of beta-emitting radiopharmaceuticals may cause significant bone marrow suppression and limit repeated administration.33 The track length of the alpha particle is 0.10 mm (five to ten cell diameters) compared with 0.6 mm for samarium-153 and 2.4 mm for strontium-89, limiting damage to normal tissues.1 Preclinical studies performed in rats demonstrated a significant bone marrow-sparing advantage with radium-223 compared with strontium-89.34 In an experimental bone metastasis model in nude rats, radium-223 was found to be selectively concentrated in bone compared with soft tissues with a dose-dependent increase in symptom-free survival observed.35

Bottom Line: Radium-223 is a first-in-class alpha particle-emitting radiopharmaceutical approved for the treatment of bone metastatic castration-resistant prostate cancer.Radium-223 is administered intravenously with no requirement for complex shielding and specifically targets areas of bone metastasis.In a randomized placebo-controlled Phase III study, treatment with radium-223 was shown to improve overall survival, time to skeletal-related events, and health-related quality of life.

View Article: PubMed Central - PubMed

Affiliation: Department of Hematology/Oncology, American University of Beirut Medical Center, Beirut, Lebanon.

ABSTRACT
Radium-223 is a first-in-class alpha particle-emitting radiopharmaceutical approved for the treatment of bone metastatic castration-resistant prostate cancer. Radium-223 is administered intravenously with no requirement for complex shielding and specifically targets areas of bone metastasis. In a randomized placebo-controlled Phase III study, treatment with radium-223 was shown to improve overall survival, time to skeletal-related events, and health-related quality of life. Apart from radium-223, the cytotoxic chemotherapy agents docetaxel and cabazitaxel, androgen biosynthesis inhibitor abiraterone acetate, novel anti-androgen enzalutamide, and immunotherapy sipuleucel-T have also been shown to improve survival of men with advanced prostate cancer in Phase III trials. This review will outline current treatment approaches for advanced prostate cancer with a focus on the role of radium-223 in changing treatment paradigms.

No MeSH data available.


Related in: MedlinePlus